Synaptic logo

Synaptic

Deal Sourcing & Portfolio Management tools for Private Investors

130 employees · est. 2016 · San Francisco, United States

VS
Syndesi Therapeutics logo

Syndesi Therapeutics

Syndesi Therapeutics is developing a drug for consecutive cognitive disorders using exclusive technology from UCB.

2-10 employees · est. 2018 · United States

Synaptic is the older company (2016 vs 2018); Synaptic is the larger of the two.

Side-by-Side Comparison

Synaptic Syndesi Therapeutics
Founded
2016 older 2018
Headquarters
San Francisco, United States United States
Employees
130 larger 2-10
Industry
Not tracked yet Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series B Series A
Total Funding
$20.00M $26.20M
Funding Rounds
1 3
Services
Startup discovery, Investment analysis, Growth signal monitoring, Founder and team insights, Portfolio IQ Not tracked yet
Target Customers
Venture capital firms, Angel investors, Private equity investors, Investment analysts, Growth funds Not tracked yet
Taxonomy
Data Intelligence, Alternative Data, Deal Sourcing, Portfolio Management, Venture Capital, Private Equity, Hedge Funds, No-Code Platform, Company Insights, Analytics Toolkit, Due Diligence, Investment Process, Research Workflow, Custom Data Integration, Sector Analysis Biopharmaceuticals, Cognitive Disorders, Neurological Conditions, Drug Development, SV2A, Synaptic Vesicle Protein, Neuroscience, Exclusive Technology, UCB, Platform Technology, Molecules, Synaptic Transmission, Neurons
Website
synaptic.com syndesitherapeutics.com
Synaptic logo

About Synaptic

Synaptic, founded in 2016, is a prominent player in the realm of data intelligence platforms tailored for private investors. The company supports crucial stages of the investment process, from deal sourcing to portfolio management, positioning itself as an indispensable tool for top-tier investors....

Syndesi Therapeutics logo

About Syndesi Therapeutics

Syndesi Therapeutics is a biotech startup founded in 2018 and based in the United States. The company's focus is on developing a drug candidate for cognitive disorders associated with various neurological conditions. It holds an exclusive license to its platform technology from UCB, a prominent rese...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Synaptic and Syndesi Therapeutics — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Synaptic and Syndesi Therapeutics — by email.

Frequently Asked Questions

Synaptic — Deal Sourcing & Portfolio Management tools for Private Investors. Syndesi Therapeutics — Syndesi Therapeutics is developing a drug for consecutive cognitive disorders using exclusive technology from UCB.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Synaptic has raised $20.00M while Syndesi Therapeutics has raised $26.20M.
Synaptic and Syndesi Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Synaptic with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy